Skip to content
2000
Volume 20, Issue 12
  • ISSN: 0929-8665
  • E-ISSN: 1875-5305

Abstract

Recombinant technology has ushered in a new era for the pharmaceutical industry. Protein therapeutics, including plasma-derived products and antibodies obtained from the serum of infected patients, have been successfully adopted and utilized to treat various indications. The development of recombinant technology and the subsequent improvement in expression, purification, and formulation technologies have enabled the generation of highly purified proteins in a scalable and cost-effective manner. The discovery and development of several recombinant proteins, such as growth factors and cytokines, will be described followed by a brief review of monoclonal antibodies and enzyme replacement therapy. Recombinant protein-based vaccine, which is the focus of the current review, is described in detail with particular emphasis on several viral and bacterial infections. Challenges and new approaches in their use as a replacement for the currently available vaccines are discussed.

Loading

Article metrics loading...

/content/journals/ppl/10.2174/092986652012131112122245
2013-12-01
2025-12-10
Loading full text...

Full text loading...

/content/journals/ppl/10.2174/092986652012131112122245
Loading

  • Article Type:
    Research Article
Keyword(s): expression systems; Recombinant proteins; therapeutic proteins; vaccines
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test